DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide

BACKGROUND: Consistently reported prognostic factors for glioblastoma (GBM) are age, extent of surgery, performance status, IDH1 mutational status, and MGMT promoter methylation status. We aimed to integrate biological and clinical prognostic factors into a nomogram intended to predict the survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Etcheverry, Amandine, Aubry, Marc, Idbaih, Ahmed, Vauleon, Elodie, Marie, Yannick, Menei, Philippe, Boniface, Rachel, Figarella-Branger, Dominique, Karayan-Tapon, Lucie, Quillien, Veronique, Sanson, Marc, de Tayrac, Marie, Delattre, Jean-Yves, Mosser, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169423/
https://www.ncbi.nlm.nih.gov/pubmed/25233099
http://dx.doi.org/10.1371/journal.pone.0104455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169423/
https://www.ncbi.nlm.nih.gov/pubmed/25233099
http://dx.doi.org/10.1371/journal.pone.0104455

Ejemplares similares